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(APL) treated using all-trans-retinoic acid (ATRA) based therapy
will relapse. An analysis of salvage therapy in patients  66 years
old from two sequential European multi-center trials demonstrated
the efﬁcacy of autologous peripheral blood stem cell transplant
(PBSCT) performed during molecular remission.
Since 2004, APL recurred in four patients following ATRA based
therapy. Table 1 (below) summarizes their clinical characteristics.
After achieving molecular remission, the patients received cyclo-
phosphamide 2 gm/m2 for two days followed by G-CSF mobili-
zation. All PBSC products were negative for PML-RARA by RT-
PCR. To date, three patients received stem cell infusions following
cyclophosphamide (60 mg/kg X 2 days) and total body irradiation
(200 cGy X 6).
All three transplanted patients remain in molecular remission 27,
13, and 8 months following PBSCT. Engraftment of WBC oc-
curred at 13, 15 and 18 days, with discharge days of 16, 18, and 20
post-PBSCT. Maximum toxicity was Grade III mucositis (NCI
CTC v.3.0).
PML-RARA negative stem cells can be mobilized in pediatric
patients after arsenic trioxide or FLAG therapy using cyclophos-
phamide and G-CSF. Three patients have durable molecular re-
mission following PBSCT. Autologous PBSCT is an option for
pediatric patients with relapsed APL that avoids the complications
of graft vs host disease, prolonged immunosuppression, and the
higher transplant related mortality of allogeneic transplantation.
Table 1. Clinical characteristcs, salvage therapies and mobilization
outcome.
Age at dx
(yrs)/gender
Sanz Risk
Group1
Length
CR 1
(mos)
Relapse
Site
Re-induction
therapy
# days
harvested
Total
CD34/kg
X 106
14 M High 11 Marrow
 CNS
Arsenic trioxide
 Intrathecal
Ara-C
3 2.19
15 M Intermediate 24 Marrow Arsenic trioxide 3 2.35
2 M Intermediate 14 CNS FLAG2 
Intrathecal Ara-
C and
Methotrexate
1 207.00
12 M Low 26 Marrow Arsenic
Trioxide
1 14.53
1 Sanz, Blood 2000: 96(4), 1247-1253 2 FLAG (ﬂudarabine 25
mg/m2 X 5 days; cytarabine 2 gm/m2 X 5 days; G-CSF)
183
HIGH-DOSE THIOTEPA, BUSULFAN, AND CYCLOPHOSPHAMIDE FOR
ALLOGENEIC STEM CELL TRANSPLANTION IN RISK PEDAITRIC PA-
TIENTS WITH HIGH-RISK LEUKEMIAS
Worth, L.L.1, Koontz, S.E.1, Petropoulos, D.1, Tran, H.T.1,
Choroszy, M.S.1, Chan, K.2 1University of Texas M D Anderson Cancer
Center, Houston, TX; 2Texas Transplant Institute, San Antonio, TX.
Between 1992 and 2003, 50 children at M D Anderson Cancer
Center with high-risk leukemias received thiotepa (250 mg/m2 x 3),
busulfan (1 mg/kg q 6 hrs x 12 orally or 0.8 mg/kg q 6 hrs iv x 12),
and cyclophosphamide (60mg/kg x 2) as a preparative regimen for
allogeneic stem cells transplantation. High-risk ALL patients (25)
had abnormal cytogenetics (Ph, 11q23), CR2 after early relapse,
 CR3, or were induction failures. Patients will AML (25) were
included if they had CR 2, MDS, or were induction failures.
Sixteen patients were transplanted with active disease ( 5% blasts
on bone marrow aspirate). Busulfan was given orally until 1999
when the intravenous preparation was available. Stem cell sources
included HLA matched family members (21) and unrelated mar-
row and cord blood (29). Two patients failed to engraft and went
on to receive a second transplant. Neutrophil engraftment (ANC
500) occurred at a median of 17.5 days (range 11-63) and platelet
counts50,000/L at a median of 44.5 days (range 13-394). Grade
3-4 toxicities occurred in 24 patients and were predominantly
esophagitis and mucositis, emesis, and hepatic dysfunction. All
three patients who developed VOD had received busulfan orally.
One patient did not have pharmacokinetics performed secondary
to machine malfunction. One patient had an acceptable AUC. The
ﬁnal patient had an elevated BU dose that was decreased based on
initial pharmacokinetics. Grades I -II acute GVHD was common
(27 patients). Grades III-IV occurred in 5 patients. Five patients
developed limited chronic GVHD, and 9 patients developed ex-
tensive chronic GVHD. Nineteen patients are alive and well a
median of 7.0 years (range 3.0 - 13.9). Thirty-one patients died of
recurrent disease (13), infection (6), GVHD (5), VOD (3), other
causes (4). The two patients who failed to engraft and underwent a
second transplant died of disease recurrence. Children with high-
risk leukemias are difﬁcult to cure even with high-dose chemother-
apy and stem cell transplantation. Of the 16 patients transplanted
with active disease, only the patients with AML are long term
survivors, suggesting that this regimen alone will not result in a
cure, but that additional strategies are required for children with
active ALL. This chemotherapeutic regimen had some signiﬁcant
toxicities, however, after the development of intravenous busulfan,
this regimen had a signiﬁcant decrease in nausea and there were no
incidence of VOD suggesting further evaluation.
184
A NOVEL RAG-1 NULL MUTANT DISPLAYS SEGREGATION OF DNA
CLEAVAGE INTO TRANSPOSITION ACTIVITY IN THREE CHILDREN WITH
T-B-NKSCID
Xiao, T.Z.1, Dunn, E.A.1, Yannone, S.M.2, Cowan, M.J.1 1Pediatric
Bone Marrow Transplant Division, UCSF Children’s Hospital, 505
Parnassus Ave, San Francisco, CA; 2Life Sciences Division, Department
of Molecular Biology, Lawrence Berkeley National Laboratory, 1 Cyclo-
tron Road, Berkeley, CA.
RAG (recombination activating gene)-1 and RAG-2 initiate
V(D)J recombination by cleaving DNA at recombination signal
sequences (RSS) through sequential nicking and transesteriﬁcation
reactions to yield blunt signal and coding ends terminating in DNA
hairpin structures. Ubiquitous DNA double strand repair factors in
the non-homologous ending joining (NHEJ) pathway then medi-
ate the rejoining of broken DNA. Severe combined immunodeﬁ-
ciency disease (SCID) comprises a heterogeneous group of primary
immunodeﬁciencies, a proportion of which are due to mutations in
RAG-1, RAG-2 or in NHEJ factors, respectively. Here, we report
a novel RAG-1 null mutation, R776W, identiﬁed in three familial
related children from the Dine´ Native American tribe who mani-
fest a classic T-B-NKSCID phenotype and engraftment of ma-
ternal T cells. Unlike Artemis mutations among Athabascan-speak-
ing Native Americans, which trigger accumulation of the hairpin
structure, this RAG-1 null mutant evokes impaired DNA cleavage
and binding activity in vitro by preferentially diminishing hairpin
formation. Moreover, the V(D)J recombination efﬁciency of this
mutant is also reduced as assessed by an enhanced green ﬂuores-
cent protein (EGFP) based V(D)J recombination assay. However,
the catalysis of other DNA strand transfer reaction, such as trans-
position, is not substantially affected by this RAG-1 mutant. These
results indicate that dysfunction of RAG-1 is responsible for the
T-B-NKSCID phenotype. Segregation of RAG-1 mediated DNA
cleavage activity into its transposition activity casts a new light on
RAG-1’s roles in V(D)J recombination and translocation.
SOLID TUMORS
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FEASIBILITY OF AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED
BY REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION
FOR HIGH RISK NEUROBLASTOMA: A SINGLE INSTITUTION PILOT
STUDY
Yamashiro, D.J.1, Lee, A.1, Bhatia, M.1, Glade-Bender, J.1,
Qualter, E.1, Militano, O.1, Harrison, L.A.1, Davenport, V.1,
Cheung, K.1, Bradley, M.B.1, Garvin, J.H.1, Del Toro, G.1,
Cairo, M.S.1 1Columbia University, New York, NY.
Background: Autologous stem cell transplant (AutoSCT) has
improved the outcome for children with high risk (HR) neuroblas-
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toma (NB) but long term event free survival remains unsatisfac-
tory. Novel approaches to consolidation and minimal residual
disease therapy are urgently needed. AutoSCT combined with
reduced intensity allogeneic stem cell transplantation (RIAlloSCT)
has the potential to confer a durable graft versus tumor immunity,
but is thought to be limited by signiﬁcant toxicity. We have
investigated the feasibility of consolidation with sequential Auto-
SCT/RIAlloSCT in newly diagnosed patients with HR NB.
Methods: Induction chemotherapy was based on a modiﬁed N7
regimen, with patients obtaining at least a PR eligible for consol-
idation. AutoSCT regimen was: Topotecan 1.5 mg/m2x5d, Car-
boplatin 500 mg/m2x3d, and Thiotepa 300 mg/m2x3d. Siblings
and unrelated cord blood (UCB) units were considered as donor
sources. RIAlloSCT conditioning was: Fludarabine 30 mg/m2x5d,
Busulfan IV 3.2 mg/kgx2d, and Rabbit Anti-thymocyte globulin 2
mg/kgx4d (UCB recipients only). GVHD prophylaxis was Tacroli-
mus and Mycophenolate mofetil. Post-AlloSCT patients received
local RT and cis-retinoic acid. Results: 9 patients have enrolled, of
which 5 received both transplants (1 withdrew prior to RIAlloSCT;
1 progressed after AutoSCT; 2 did not achieve a PR with Induc-
tion). Median time to RIAlloSCT after AutoSCT was 79d (67-
93d). Donor characteristics: UCB 4/6, 5/6, 6/6; related donor 5/6,
6/6 HLA matched. Maximal peripheral chimerism was 99-100%. 4
of 5 patients had some evidence of GVHD. Maximal grade for
acute GVHD: skin and gut, grade 3 (n2), skin only, grade 1
(n1). One patient had chronic liver GVHD. All 5 patients are
alive, with no evidence of disease, with median time from diagnosis
of 41m (26m-50m) [Table 1]. Conclusion: AutoSCT followed by
RIAlloSCT appears feasibile in patients with HR NB. Additional
study of this approach in this group of patients is warranted.
RIAlloSCT Recipients
Age at Dx Stage MYCN Resp PreAllo Mo from Dx
22 mo 4 Amp CR 50
13 mo 4 Amp CR 43
62 mo 4 NonAmp PR 41
21 mo 4 Amp VGPR 40
28 mo 3 Amp PR 26
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SUPERIOR ANTITUMOR IN VITRO RESPONSES OF ALLOGENEIC
MATCHED SIBLING COMPARED TO AUTOLOGOUS PATIENT CD8 T
CELLS
Kausche, S.1, Wehler, T.C.1, Schnuerer, E.1, Lennerz, V.1,
Groene, M.1, Nonn, M.1, Meyer, R.G.1, Huber, C.1, Herr, W.1 1Uni-
versity of Mainz - Department of Medicine III, Mainz, Germany.
Allogeneic cell therapy as a means to break immunotolerance to
solid tumors is increasingly used for cancer treatment. To inves-
tigate cellular alloimmune responses in a human tumor model,
primary cultures were established from renal-cell carcinoma
(RCC) tissues of 56 patients. In 3 patients with stable RCC line and
HLA-identical sibling donor available, allogeneic and autologous
RCC reactivities were compared using mixed lymphocyte/tumor-
cell cultures (MLTCs). In addition to peripheral blood lympho-
cytes, tumor-inﬁltrating lymphocytes were included in the analy-
ses. Responding MLTC lymphocytes were exclusively CD8 T
cells, whereas CD4 T cells or NK cells were never observed.
Sibling MLTC populations showed higher proliferative and cyto-
lytic antitumor responses compared to their autologous counter-
parts. The proportion of CD4CD25FOXP3 regulatory T cells
did not signiﬁcantly differ between autologous and allogeneic lym-
phocyte samples, providing no sufﬁcient explanation for the ob-
served hyperresponsiveness of sibling CD8 T cells. The sibling
MLTC responders originated from the CD8CD62L(high) pe-
ripheral-blood subpopulation containing naive precursor and cen-
tral memory T cells. Limiting dilution cloning failed to establish
cytotoxic T-lymphocyte (CTL) clones from autologous MLTCs
or tumor-inﬁltrating lymphocytes. In contrast, a broad panel of
RCC-reactive CTL clones were expanded from each allogeneic
MLTC. These sibling CTL clones recognized either exclusively
the original RCC tumor line or cross-reacted with non-malignant
kidney cells of patient origin. A minority of CTL clones also
recognized patient-derived hematopoietic cells or other allogeneic
tumor targets. The MHC-restricting alleles for RCC-reactive sib-
ling CTL clones included HLA-A2, -A3, -A11, -A24, and -B7. In
one sibling donor-RCC pair, strongly proliferative
CD3CD16CD57 CTL clones with non-HLA restricted anti-
tumor reactivity were established. Taken together, our results
demonstrate superior tumor-reactive CD8 responses of matched
allogeneic compared to autologous T cells. These data encourage
the generation of antitumor T-cell products from HLA-identical
siblings and their potential use in adoptive immunotherapy of
metastatic RCC patients.
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IN-VITRO ASSESSMENT OF THE EFFECTIVENESS OF BUSULFAN (BU) TO
INDUCE APOPTOSIS AND NECROSIS IN NEUROBLASTOMA (NBL) CELL
LINES AND PRIMARY TUMORS
Olszewski, M.1, Jackson, C.1, Huang, W.1, Tallman, S.1, Kletzel, M.1,2
1Children’s Memorial Hospital Stem Cell Processing and Graft Engi-
neering Laboratory, Chicago, IL; 2Northwestern University Feinberg
School of Medicine, Chicago, IL.
Busulfan is an alkylating agent used routinely before hematopoi-
etic progenitor stem cell transplants. Because the effects of Bu on
NBL cells in the literature is controversial, this study sought to
evaluate the use of Bu to induce apoptosis and necrosis in NBL cell
lines and primary tumors.
NBL cell lines (SKN/DOX-R, SKN/SH, IMR-5 and NGP) and
two NBL primary tumors (M-line and S-line) were harvested and
transferred to 24-well culture plates at a density of 106 cells/ml.
Cells were incubated without Bu (control) and with concentrations
of 0.001, 0.01, and 0.1 mg/ml of Bu. Two methods were used. Flow
cytometry was used to assess cells for apoptosis and necrosis, using
Annexin V and Propidium Iodide (PI), respectively, after 6, 24, 48,
and 72 hours (only 24 hour result shown). Cell viability was also
measured using a MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide) drug sensitivity assay.
Results indicated increased apoptosis and necrosis in cell lines
SKN/SH, SKN/DOX-R, and S-line when compared to the con-
trols at 24 hours (See table). MTT assay demonstrated signiﬁcant
decreased viability with the same cell lines (p-values0.05; 0.037,
0.028, and 0.045, respectively), and no signiﬁcant correlation with
the others.
The ﬁndings suggest that Bu is an effective drug against NBL cell
lines SKN/DOX-R, SKN/SH, and primary tumor S-line at 24
hours. Increasing concentrations show increasing cell death in
these sensitive cell lines. Other cell lines IMR-5, NGP, and pri-
mary tumor M-line did not demonstrate increased cell death with
increased Bu concentrations at 24 hours. Further analysis will
determine if other concentrations and time points show greater
sensitivity of NBL cells to Bu.
Mean Percent Cell Viability compared to Busulfan Concentration at
24 Hours
SKN/SH SKN/DOX-R S-line IMR-5 NGP M-line
0 mg/ml 68 81 50 58 92 56
0.001 mg/ml 26 41 31 64 72 48
0.01 mg/ml 21 27 25 50 88 56
0.1 mg/ml 18 28 21 59 80 59
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STIMULATION OF ANTI-TUMOR IMMUNITY USING DENDRITIC CELL/
TUMOR FUSIONS AND ANTI CD3/CD28
Rosenblatt, J.1, Wu, Z.2, Lenahan, C.1, Vasir, B.2, Bisonette, A.2,
Kufe, D.2, Avigan, D.1 1Beth Israel Deaconess Medical Center, Boston,
MA; 2Dana Farber Cancer Institute, Boston, MA.
We have demonstrated that fusions of patient derived renal cell
carcinoma (RCC) and autologous dendritic cells (DCs) stimulate
anti-tumor immune responses and disease response in a subset of
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